{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:22:44Z","timestamp":1791177764302,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002460","name":"Chung-Ang University","doi-asserted-by":"publisher","award":["Research Grants in 2024"],"award-info":[{"award-number":["Research Grants in 2024"]}],"id":[{"id":"10.13039\/501100002460","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04852-3","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:04:11Z","timestamp":1777471451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serial aqueous VEGF analysis for predicting anti-VEGF treatment outcomes in neovascular glaucoma from diabetic retinopathy: a prospective analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Taesung","family":"Joo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ho","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"4852_CR1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081\u201390. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.013.","journal-title":"Ophthalmology"},{"key":"4852_CR2","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/nejm199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480\u20137. https:\/\/doi.org\/10.1056\/nejm199412013312203.","journal-title":"N Engl J Med"},{"key":"4852_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.preteyeres.2007.06.001","volume":"26","author":"SS Hayreh","year":"2007","unstructured":"Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007;26:470\u201385. https:\/\/doi.org\/10.1016\/j.preteyeres.2007.06.001.","journal-title":"Prog Retin Eye Res"},{"key":"4852_CR4","doi-asserted-by":"publisher","unstructured":"Cabral T, et al. Retinal and choroidal angiogenesis: a review of new targets. Int J Retina Vitreous. 2017;3. https:\/\/doi.org\/10.1186\/s40942-017-0084-9.","DOI":"10.1186\/s40942-017-0084-9"},{"key":"4852_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/s0161-6420(98)92782-8","volume":"105","author":"RC Tripathi","year":"1998","unstructured":"Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232\u20137. https:\/\/doi.org\/10.1016\/s0161-6420(98)92782-8.","journal-title":"Ophthalmology"},{"key":"4852_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10792-019-01207-4","volume":"40","author":"C Sun","year":"2020","unstructured":"Sun C, et al. Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy. Int Ophthalmol. 2020;40:467\u201375. https:\/\/doi.org\/10.1007\/s10792-019-01207-4.","journal-title":"Int Ophthalmol"},{"key":"4852_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/IJG.0b013e3181895e5c","volume":"18","author":"YG Kim","year":"2009","unstructured":"Kim YG, et al. Level of vascular endothelial growth factor in aqueous humor and surgical results of ahmed glaucoma valve implantation in patients with neovascular glaucoma. J Glaucoma. 2009;18:443\u20137. https:\/\/doi.org\/10.1097\/IJG.0b013e3181895e5c.","journal-title":"J Glaucoma"},{"key":"4852_CR8","doi-asserted-by":"publisher","unstructured":"Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26(3):352\u20134. https:\/\/doi.org\/10.1097\/00006982-200603000-00016 (2006).","DOI":"10.1097\/00006982-200603000-00016"},{"key":"4852_CR9","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.ophtha.2008.02.026","volume":"115","author":"T Wakabayashi","year":"2008","unstructured":"Wakabayashi T, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115:1571\u201380. https:\/\/doi.org\/10.1016\/j.ophtha.2008.02.026. 1580.e1571. 1573.","journal-title":"Ophthalmology"},{"key":"4852_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/bjo.2008.145714","volume":"93","author":"S Grover","year":"2009","unstructured":"Grover S, Gupta S, Sharma R, Brar VS, Chalam KV. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol. 2009;93:273\u20134. https:\/\/doi.org\/10.1136\/bjo.2008.145714.","journal-title":"Br J Ophthalmol"},{"key":"4852_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10384-008-0645-4","volume":"53","author":"K Matsuyama","year":"2009","unstructured":"Matsuyama K, et al. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn J Ophthalmol. 2009;53:243\u20138. https:\/\/doi.org\/10.1007\/s10384-008-0645-4.","journal-title":"Jpn J Ophthalmol"},{"key":"4852_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/jop.2011.0059","volume":"28","author":"Y Sasamoto","year":"2012","unstructured":"Sasamoto Y, et al. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study. J Ocul Pharmacol Ther. 2012;28:41\u20138. https:\/\/doi.org\/10.1089\/jop.2011.0059.","journal-title":"J Ocul Pharmacol Ther"},{"key":"4852_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2021-egsguidelines","volume":"105","author":"European Glaucoma Society","year":"2021","unstructured":"European Glaucoma Society. Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021;105:1\u2013169. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-egsguidelines.","journal-title":"Br J Ophthalmol"},{"key":"4852_CR14","doi-asserted-by":"publisher","unstructured":"Rodrigues GB, et al. Neovascular glaucoma: a review. Int J Retina Vitreous. 2016;2:26. https:\/\/doi.org\/10.1186\/s40942-016-0051-x.","DOI":"10.1186\/s40942-016-0051-x"},{"key":"4852_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000431196","volume":"55","author":"SJ Havens","year":"2016","unstructured":"Havens SJ, Gulati V. Neovascular Glaucoma. Dev Ophthalmol. 2016;55:196\u2013204. https:\/\/doi.org\/10.1159\/000431196.","journal-title":"Dev Ophthalmol"},{"key":"4852_CR16","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s10792-021-01789-y","volume":"41","author":"PK Rani","year":"2021","unstructured":"Rani PK, et al. Outcomes of neovascular glaucoma in eyes presenting with moderate to good visual potential. Int Ophthalmol. 2021;41:2359\u201368. https:\/\/doi.org\/10.1007\/s10792-021-01789-y.","journal-title":"Int Ophthalmol"},{"key":"4852_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1755-3768.2010.01918.x","volume":"89","author":"T Yilmaz","year":"2011","unstructured":"Yilmaz T, Cordero-Coma M, Gallagher MJ, Teasley LA. Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. Acta Ophthalmol. 2011;89:709\u201317. https:\/\/doi.org\/10.1111\/j.1755-3768.2010.01918.x.","journal-title":"Acta Ophthalmol"},{"key":"4852_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/0974-9233.53865","volume":"16","author":"AA Ghanem","year":"2009","unstructured":"Ghanem AA, El-Kannishy AM, El-Wehidy AS, El-Agamy AF. Intravitreal bevacizumab (avastin) as an adjuvant treatment in cases of neovascular glaucoma. Middle East Afr J Ophthalmol. 2009;16:75\u20139. https:\/\/doi.org\/10.4103\/0974-9233.53865.","journal-title":"Middle East Afr J Ophthalmol"},{"key":"4852_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1365-2125.2008.03278.x","volume":"66","author":"C Costagliola","year":"2008","unstructured":"Costagliola C, et al. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol. 2008;66:667\u201373. https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03278.x.","journal-title":"Br J Clin Pharmacol"},{"key":"4852_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/IJG.0b013e3181997211","volume":"18","author":"S Yazdani","year":"2009","unstructured":"Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma. 2009;18:632\u20137. https:\/\/doi.org\/10.1097\/IJG.0b013e3181997211.","journal-title":"J Glaucoma"},{"key":"4852_CR21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/ceo.12559","volume":"43","author":"JR SooHoo","year":"2015","unstructured":"SooHoo JR, Seibold LK, Pantcheva MB, Kahook M. Y. Aflibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2015;43:803\u20137. https:\/\/doi.org\/10.1111\/ceo.12559.","journal-title":"Clin Exp Ophthalmol"},{"key":"4852_CR22","doi-asserted-by":"publisher","unstructured":"Ticly FG, Lira RPC, Fulco EAM, Vasconcelos JP. Intravitreal ranibizumab as adjuvant treatment for neovascular glaucoma. C. d. 72:119\u201321. https:\/\/doi.org\/10.1590\/s0034-72802013000200010 (2013).","DOI":"10.1590\/s0034-72802013000200010"},{"key":"4852_CR23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2007.01.017.","journal-title":"Ophthalmology"},{"key":"4852_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2147\/opth.s19555","volume":"5","author":"CI Sinapis","year":"2011","unstructured":"Sinapis CI, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin\u00ae) in rabbits. Clin Ophthalmol. 2011;5:697\u2013704. https:\/\/doi.org\/10.2147\/opth.s19555.","journal-title":"Clin Ophthalmol"},{"key":"4852_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00417-013-2495-0","volume":"252","author":"E Moisseiev","year":"2014","unstructured":"Moisseiev E, et al. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefes Arch Clin Exp Ophthalmol. 2014;252:331\u20137. https:\/\/doi.org\/10.1007\/s00417-013-2495-0.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4852_CR26","first-page":"4936","volume":"48","author":"KG Csaky","year":"2007","unstructured":"Csaky KG, Gordiyenko N, Rabena MG, Avery RL. Pharmacokinetics of Intravitreal Bevacizumab in Humans. Investig Ophthalmol Vis Sci. 2007;48:4936\u20134936.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4852_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","volume":"146","author":"TU Krohne","year":"2008","unstructured":"Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508\u201312. https:\/\/doi.org\/10.1016\/j.ajo.2008.05.036.","journal-title":"Am J Ophthalmol"},{"key":"4852_CR28","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s10384-018-0619-0","volume":"62","author":"M Mimouni","year":"2018","unstructured":"Mimouni M, et al. Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing. Jpn J Ophthalmol. 2018;62:652\u20138. https:\/\/doi.org\/10.1007\/s10384-018-0619-0.","journal-title":"Jpn J Ophthalmol"},{"key":"4852_CR29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/iae.0b013e31822c290f","volume":"32","author":"MW Stewart","year":"2012","unstructured":"Stewart MW, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina (Philadelphia Pa). 2012;32:434\u201357. https:\/\/doi.org\/10.1097\/iae.0b013e31822c290f.","journal-title":"Retina (Philadelphia Pa)"},{"key":"4852_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3129\/i10-024","volume":"45","author":"W Xu","year":"2010","unstructured":"Xu W, et al. Testing toxicity of multiple intravitreal injections of bevacizumab in rabbit eyes. Can J Ophthalmol. 2010;45:386\u201392. https:\/\/doi.org\/10.3129\/i10-024.","journal-title":"Can J Ophthalmol"},{"key":"4852_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ajo.2014.10.005","volume":"159","author":"A Barikian","year":"2015","unstructured":"Barikian A, Mahfoud Z, Abdulaal M, Safar A, Bashshur ZF. Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:131\u20137. https:\/\/doi.org\/10.1016\/j.ajo.2014.10.005.","journal-title":"Am J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04852-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:59:22Z","timestamp":1777625962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04852-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4852"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04852-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8711380\/v1","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current research followed the tenets of the Declaration of Helsinki, and all patients provided informed consent after an explanation of the study protocol. The Institutional Review Board at Kyung Hee University Hospital at Gangdong (KHNMC 2016-12-021) approved this prospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}